Cassava Sciences said the FDA had placed a hold on its trial for a drug to treat epilepsy. Shares slid 13% to $2.49 after the bell. KB Home delivered fewer homes and recorded a lower profit in its ...
StockStory.org on MSN
Nike’s (NYSE:NKE) Q4 CY2025 sales beat estimates
Athletic apparel brand Nike (NYSE:NKE) announced in Q4 CY2025, but sales were flat year on year at $12.43 billion. Its GAAP ...
Zacks Investment Research on MSN
Can Nike's digital expansion strategy reignite consumer engagement?
NIKE, Inc.’s NKE digital ecosystem remains a powerful engagement engine and has long been positioned as a core pillar of its growth strategy. However, the company has been experiencing a sustained ...
New York fintech firm Bilt has created a loyal following of its original series "Roomies," which it produces in-house and ...
The anticipated weak figures are a direct consequence of a complex corporate restructuring. Nike's "Win Now" strategy involves a course correction, moving back toward stronger wholesale partnerships ...
Nike focuses on boosting its marketing budget to regain market share after struggling against rivals like On and Hoka.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback